These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2039968)

  • 1. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
    Changchine CS; Yung CY; Tzen KY
    Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
    Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
    Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis.
    Shimizu M; Saitoh Y; Ohyanagi H; Itoh H
    Arch Pathol Lab Med; 1990 Feb; 114(2):195-200. PubMed ID: 1689141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoembryonic antigen and carbohydrate antigen 19-9 levels of peripheral and draining venous blood in colorectal cancer patients. Correlation with histopathologic and immunohistochemical variables.
    Tabuchi Y; Deguchi H; Saitoh Y
    Cancer; 1988 Oct; 62(8):1605-13. PubMed ID: 3167774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
    Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
    J Med; 1991; 22(3):145-56. PubMed ID: 1770322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas.
    Wang JY; Chen FZ; Yang YZ
    Chin Med J (Engl); 1990 Oct; 103(10):817-20. PubMed ID: 2125254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
    Steinberg WM; Gelfand R; Anderson KK; Glenn J; Kurtzman SH; Sindelar WF; Toskes PP
    Gastroenterology; 1986 Feb; 90(2):343-9. PubMed ID: 2416628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.
    Banfi G; Bravi S; Ardemagni A; Zerbi A
    Int J Biol Markers; 1996; 11(2):77-81. PubMed ID: 8776607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits of CEA and ferritin in the diagnosis of pancreatic cancer.
    Plebani M; Fabris C; Basso D; Del Favero G; Angonese C; Leandro G; Di Mario F; Burlina A; Naccarato R
    Int J Pancreatol; 1988; 3 Suppl 1():S113-7. PubMed ID: 3209864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
    Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
    Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
    Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
    Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen (CEA) activity in pancreatic juice of patients with pancreatic carcinoma and pancreatitis.
    Sharma MP; Gregg JA; Loewenstein MS; McCabe RP; Zamcheck N
    Cancer; 1976 Dec; 38(6):2457-61. PubMed ID: 1000475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
    Haglund C
    Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.